Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, continues to challenge health systems worldwide. The rising prevalence, high treatment costs, and unpredictable nature of flare-ups make coordinated, preventive care strategies more urgent than ever. Payers are increasingly shifting toward value-based designs, providers are looking for tools to improve adherence, and patients are seeking alternatives that complement traditional therapies.

In this environment, partnerships that bridge clinical evidence with real-world care delivery are gaining traction. The latest example comes from Evinature and SonarMD, who announced a new pilot aiming to weave nutraceutical science directly into digital care pathways for chronic GI conditions.

A Collaboration Rooted in Evidence and Real-World Need

Evinature, known for its clinically researched CurQD® formulation, is already referenced in the European ECCO Nutritional Guidelines and used in over 40 U.S. medical centers. Meanwhile, SonarMD has built a reputation as a leading care-coordination platform that partners with gastroenterologists and health plans to keep high-risk patients out of the hospital.

The pilot project seeks to integrate CurQD® into SonarMD’s continuous, digital care model. This move could create a real-time feedback loop between patients, providers, and a nutraceutical therapy supported by peer-reviewed research.

Under the initiative, CurQD protocols may be offered to eligible patients seen by SonarMD’s partnering GI providers. SonarMD will help facilitate the program while collecting real-world data that may shed light on three critical areas:

• Patient well-being and satisfaction
• Medication and treatment adherence
• Reduction of avoidable, high-cost settings, such as ER visits or inpatient admissions
  
   

For a condition like IBD, where flare management and early intervention are paramount, these outcomes could significantly influence care models across payers and integrated delivery systems.

Voices From the Partnership

Both companies framed the initiative as a step toward expanding patient choice and strengthening value-based GI care.

Beth Houck, CEO of SonarMD, stated, “Our partnership with Evinature represents an opportunity to provide patients with access to clinically-validated alternatives for their chronic disease.”

Meanwhile, Nir Salomon, Co-Founder of Evinature, echoed the sentiment, saying:  “This collaboration exemplifies our mission to bridge scientific rigor with real-world healthcare delivery. Integrating CurQD into patients’ care pathway allows us to examine how clinically studied nutritional interventions can contribute to improved patient experience and value for providers and payers.”

Why This Pilot Matters in a Value-Based Era

The U.S. healthcare system continues its shift toward accountability for outcomes, especially in chronic disease management, where high-cost utilization is both common and preventable. Gastroenterology is no exception. Payers increasingly reward early intervention and proactive monitoring, which are core capabilities of SonarMD’s model.

By incorporating a nutraceutical intervention with clinical validation, this pilot could help demonstrate how data-supported adjunct therapies can fit naturally into value-based frameworks. Unlike pharmaceuticals, nutraceuticals often lack structured clinical integration and monitoring. This collaboration changes that equation, placing CurQD within a coordinated, patient-centric environment backed by real-world data collection.

If the findings are promising, the model could scale quickly. The companies expect the pilot, which is set to launch in early 2026, to inform broader deployment across payer networks and integrated delivery systems, creating a template for blending clinical research, alternative therapies, and coordinated digital care.

Conclusion: A Quiet but Meaningful Shift in Chronic GI Care

This initiative signals a subtle but meaningful evolution in IBD care: one in which rigorously studied nutraceuticals are no longer peripheral but are integrated into digital pathways that emphasize prevention, adherence, and patient engagement.

As the healthcare industry continues to seek solutions balancing cost, outcomes, and patient preference, partnerships like that between Evinature and SonarMD may help define a new standard, one that blends scientific evidence with real-time, tech-enabled care models.

If successful, this pilot could become a blueprint for how complementary therapies find their place in the next generation of coordinated, value-based gastrointestinal care.